DrugBiological
Granulocyte-Macrophage Colony-Stimulating Factor clinical trials
- studies test it
- 118
- open now
- 11
- in phase 3
- 5
- first study started
- 1998
Keep track of what changes. Save the Granulocyte-Macrophage Colony-Stimulating Factor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
117 studies that test it; most in 2004 (12)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 3 |
| 2001 | 2 |
| 2002 | 5 |
| 2003 | 4 |
| 2004 | 12 |
| 2005 | 3 |
| 2006 | 7 |
| 2007 | 8 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 7 |
| 2012 | 7 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 9 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 7 |
| 2022 | 7 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 31
- Phase 2
- 85
- Phase 3
- 5
- Phase 4
- 5
- No phase
- 7
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 13
Who runs them
Industry 19 · Other 99
M.D. Anderson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (5) · Emory University (5) · Second Affiliated Hospital of Soochow University (4) · Sellas Life Sciences Group (3) · The Methodist Hospital Research Institute (3) · University of Virginia (3) · University Hospital Tuebingen (3)
Often tested with
Tested in the same studies.
Interleukin-2 (9) · Cyclophosphamide (8) · Naxitamab (5) · Rituximab (5) · Ipilimumab (4) · Dinutuximab (4) · Temozolomide (4) · Pembrolizumab (3)
Studies
Open first, then newest update. How each study uses Granulocyte-Macrophage Colony-Stimulating Factor is read from its arms, and is right about nine times in ten.
Testing it · 118
- A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With NeuroblastomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04936529Written as GM-CSF
- Autologous Stem Cell Transplantation in Patients With Systemic SclerosisRecruitingPhase 2Paul SzabolcsNCT03630211Written as GM-CSF
- Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT07749365Written as hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialRecruitingPhase 2New Approaches to Neuroblastoma Therapy ConsortiumNCT06450041Written as GM-CSF
- Quadruple Immunotherapy for NeuroblastomaRecruitingPhase 2Hong Kong Children's HospitalNCT05754684Written as Granulocyte-Macrophage Colony-Stimulating Factor
- Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar ProteinosisNot yet recruitingPhase 2Jiuwu BaiNCT06989333Written as GM-CSF (granulocyte-macrophage colony-stimulating factor)
- The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving RadiotherapyRecruitingPhase 2Sun Yat-sen UniversityNCT06472739Written as GM-CSF
- PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)Not yet recruitingPhase 1/2Second Affiliated Hospital of Soochow UniversityNCT06345599Written as Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab
- Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck TumorsRecruitingPhase 2Xiangpan LiNCT05760196Written as GM-CSF
- PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.Not yet recruitingPhase 2Second Affiliated Hospital of Soochow UniversityNCT05530200Written as GM-CSF
- ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and PembrolizumabNot yet recruitingPhase 2Epitopoietic Research CorporationNCT05366062Written as GM-CSF
- Therapy for Children With Advanced Stage NeuroblastomaCompletedPhase 2St. Jude Children's Research HospitalNCT01857934Written as GM-CSF
- Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial DiseaseCompletedPhase 2Emory UniversityNCT03304821Written as GM-CSF
- Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent OsteosarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT02502786Written as GM-CSF
- Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone MarrowActive, not recruitingPhase 2Y-mAbs TherapeuticsNCT03363373Written as GM-CSF + Naxitamab
- Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSFCompletedPhase 1/2Beth Israel Deaconess Medical CenterNCT00458536Written as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
- GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS StudyCompletedPhase 4Nationwide Children's HospitalNCT03769844Written as GM-CSF
- GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODSCompletedPhase 3Nationwide Children's HospitalNCT05266001Written as GM-CSF
- A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including NeuroblastomaCompletedPhase 1/2Eli Lilly and CompanyNCT04238819Written as GM-CSF
- Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk NeuroblastomaActive, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT01757626Written as Hu3F8 With GM-CSF
See all 118 studies that test Granulocyte-Macrophage Colony-Stimulating Factor →
Given in every arm · 50 — Granulocyte-Macrophage Colony-Stimulating Factor is usual care beside what is tested
- A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer BurdenNot yet recruitingPhase 2University of WashingtonNCT07721259Written as Recombinant Granulocyte-Macrophage Colony-Stimulating Factor
- Tebentafusp-tebn With LDT in Metastatic UMRecruitingPhase 1/2Thomas Jefferson UniversityNCT06626516Written as GM-CSF (Sargramostim)
- DC/MM Fusion Vaccine With BCMA CAR-T in R/R MMRecruitingPhase 1David AviganNCT07377435Written as GM-CSF
- A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple MyelomaRecruitingPhase 1David AviganNCT06799026Written as GM-CSF
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AMLRecruitingPhase 1David AviganNCT07374029Written as GM-CSF
- Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesRecruitingPhase 1Medical College of WisconsinNCT05544968Written as GM-CSF
- A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In SituRecruitingPhase 1Mayo ClinicNCT04144023Written as Granulocyte-Macrophage Colony-Stimulating Factor
- Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid TumorsNot yet recruitingPhase 2Second Affiliated Hospital of Soochow UniversityNCT07327411Written as GM-CSF
- Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed NeuroblastomaRecruitingPhase 2Sun Yat-sen UniversityNCT06013618Written as GM-CSF
- Cadonilimab Plus Anlotinib for R/M/P Cervical CancerRecruitingPhase 2Zhongnan HospitalNCT05817214Written as Granulocyte-Macrophage Colony-Stimulating Factor
- A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung CancerRecruitingPhase 2Second Affiliated Hospital of Soochow UniversityNCT06047860Written as Granulocyte-macrophage colony-stimulating factor subcutaneous injection
- Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian CancerNot yet recruitingPhase 2Aston Sci. Inc.NCT05794659Written as rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)
- Thymalfasin-based PRaG Mode for Advanced Refractory Solid TumorsRecruitingPhase 2Second Affiliated Hospital of Soochow UniversityNCT05790447Written as GM-CSF
- Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and ImiquimodTerminatedPhase 2Beth Israel Deaconess Medical CenterNCT00799110Written as GM-CSF
- Study of Chemoimmunotherapy for High-Risk NeuroblastomaActive, not recruitingEarly Phase 1Memorial Sloan Kettering Cancer CenterNCT03189706Written as GM-CSF
- pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate CancerActive, not recruitingPhase 2University of Wisconsin, MadisonNCT03600350Written as GM-CSF
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as GM-CSF
- A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of ChemoimmunotherapyTerminatedPhase 2Tufts Medical CenterNCT04856176Written as Granulocyte-Macrophage Colony-Stimulating Factor
- Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant MelanomaCompletedPhase 1/2Ultimovacs ASANCT02275416Written as GM-CSF
- Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersCompletedPhase 1/2Sellas Life Sciences GroupNCT03761914Written as GM-CSF
Showing 20 of 50.
As the comparator · 3 — what is tested is compared with Granulocyte-Macrophage Colony-Stimulating Factor
- Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple MyelomaCompletedPhase 2National Cancer Institute (NCI)NCT00006184Written as GMCSF (granulocyte macrophage colony stimulating factor)
- Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in MelanomaCompletedPhase 3BioVex LimitedNCT00769704Written as GM-CSF
- An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaCompletedPhase 3BioVex LimitedNCT01368276Written as Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)